Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche and GSK in MEK/BRAF melanoma combo face off

This article was originally published in Scrip

Executive Summary

Roche/Genentech and GlaxoSmithKline have both presented new data on their MEK/BRAF inhibitor combination regimens in their battle for BRAF V600 mutation-positive melanoma market at ESMO. Overall the two companies' regimens are set to change the standard of care for this indication, and with the efficacy profiles looking too tight to call, it seems that the relative side effect profiles of the two regimens will determine their eventual success.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC026489

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel